1.
Hematol Oncol Stem Cell Ther
; 13(3): 168-170, 2020 Sep.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29684339
RESUMO
Tumor lysis syndrome is a potentially lethal complication of chemotherapy, usually associated with aggressive hematologic malignancies. We describe the case of a young patient with metastatic hepatocellular cancer who developed rapid and fatal tumor lysis syndrome following initiation of sorafenib therapy. Although rare with sorafenib therapy for hepatocellular carcinoma, tumor lysis syndrome is serious complication. Patients with a high burden of disease at therapy initiation should have their metabolic parameters measured prior to starting therapy and closely followed for the first 1-2â¯weeks while being treated.
Assuntos
Carcinoma Hepatocelular , Neoplasias Hepáticas , Sorafenibe , Síndrome de Lise Tumoral/sangue , Carcinoma Hepatocelular/sangue , Carcinoma Hepatocelular/tratamento farmacológico , Evolução Fatal , Humanos , Neoplasias Hepáticas/sangue , Neoplasias Hepáticas/tratamento farmacológico , Masculino , Pessoa de Meia-Idade , Metástase Neoplásica , Sorafenibe/administração & dosagem , Sorafenibe/efeitos adversos
2.
Hematol., Transfus. Cell Ther. (Impr.)
; 41(3): 275-277, July-Sept. 2019.
Artigo
em Inglês
| LILACS
| ID: biblio-1039930
3.